Healthcare royalties company Royalty Pharma (NASDAQ: RPRX) will be reporting earnings this Wednesday before the bell. Hereโs what to look for.
Royalty Pharma missed analystsโ revenue expectations by 1.9% last quarter, reporting revenues of $578.7 million, up 7.7% year on year. It was a slower quarter for the company, with a miss of analystsโ revenue estimates.
Is Royalty Pharma a buy or sell going into earnings? Read our full analysis here, itโs free for active Edge members.
This quarter, analysts are expecting Royalty Pharmaโs revenue to grow 10.7% year on year to $625.3 million, improving from the 5.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.04 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings.
Looking at Royalty Pharmaโs peers in the branded pharmaceuticals segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 53.9%, beating analystsโ expectations by 9.6%, and Bristol-Myers Squibb reported revenues up 2.9%, topping estimates by 3.7%. Eli Lilly traded up 6% following the results while Bristol-Myers Squibb was also up 8.1%.
Read our full analysis of Eli Lillyโs results here and Bristol-Myers Squibbโs results here.
Investors in the branded pharmaceuticals segment have had steady hands going into earnings, with share prices flat over the last month. Royalty Pharma is up 4.6% during the same time and is heading into earnings with an average analyst price target of $44.10 (compared to the current share price of $37.80).
The biggest winnersโMicrosoft, Alphabet, Coca-Cola, Monster Beverageโwere all riding powerful megatrends before Wall Street caught on. Weโve just identified an under-the-radar profitable growth stock positioned at the center of the AI boom. Get it FREE here before the crowd discovers it. GO HERE NOW.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
